Aberrant lncRNA Expression in Multiple Myeloma

被引:23
作者
Meng, Hui [1 ]
Han, Lei [2 ]
Hong, Chun [1 ]
Ding, Jinya [1 ]
Huang, Qianchuan [1 ]
机构
[1] Wuhan Gen Hosp PLA, Dept Med Lab, Wuhan, Hubei, Peoples R China
[2] Wuhan Gen Hosp PLA, Med Dept, Discipline Sect, Wuhan, Hubei, Peoples R China
关键词
Long noncoding RNAs (lncRNAs); Multiple myeloma (MM); Expression; LONG-NONCODING RNA; ADVERSE PROGNOSTIC-FACTOR; MESENCHYMAL STEM-CELLS; CANCER CELLS; DNA METHYLATION; UP-REGULATION; GENE; UCA1; GROWTH; CRNDE;
D O I
10.3727/096504017X15123872205507
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Multiple myeloma (MM), a type of malignant tumor, is characterized by dysplasia of clonal plasma cells in the bone marrow. People with MM will have damaged organs or tissues due to secretion of large amounts of monoclonal immunoglobulin or fragments (M protein). Despite improved survivability by novel treatment strategies over the last decade, MM is still incurable by current therapies. Long noncoding RNAs (lncRNAs), with length of more than 200 nucleotides, have been reported to act as important regulators in many diseases, including MM. Recent studies have reported aberrant lncRNA expression in MM; these dysregulated lncRNAs can play oncogenic and/or tumor-suppressive roles in the development and progression of MM. In this article, we present a general overview on the role of lncRNAs in MM pathogenesis and discuss their potential as prognostic biomarkers and targets for treatment.
引用
收藏
页码:809 / 816
页数:8
相关论文
共 89 条
  • [1] Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation
    Avet-Loiseau, H
    Facon, T
    Grosbois, B
    Magrangeas, F
    Rapp, MJ
    Harousseau, JL
    Minvielle, S
    Bataille, R
    [J]. BLOOD, 2002, 99 (06) : 2185 - 2191
  • [2] Avet-Loiseau H, 1998, CANCER RES, V58, P5640
  • [3] Beckedorff FC, 2013, BIOSCI REP, V33
  • [4] Promoter hypermethylation of the MEG3 (DLK1/MEG3) imprinted gene in multiple myeloma
    Benetatos, Leonidas
    Dasoula, Aggeliki
    Hatzimichael, Eleftheria
    Georgiou, Ioannis
    Syrrou, Maria
    Bourantas, Konstantinos L.
    [J]. CLINICAL LYMPHOMA & MYELOMA, 2008, 8 (03) : 171 - 175
  • [5] A long nuclear-retained non-coding RNA regulates synaptogenesis by modulating gene expression
    Bernard, Delphine
    Prasanth, Kannanganattu V.
    Tripathi, Vidisha
    Colasse, Sabrina
    Nakamura, Tetsuya
    Xuan, Zhenyu
    Zhang, Michael Q.
    Sedel, Frederic
    Jourdren, Laurent
    Coulpier, Fanny
    Triller, Antoine
    Spector, David L.
    Bessis, Alain
    [J]. EMBO JOURNAL, 2010, 29 (18) : 3082 - 3093
  • [6] Pervasive lncRNA binding by epigenetic modifying complexes - The challenges ahead
    Betancur, Juan G.
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA-GENE REGULATORY MECHANISMS, 2016, 1859 (01): : 93 - 101
  • [7] Long non-coding RNA PCAT-1 over-expression promotes proliferation and metastasis in gastric cancer cells through regulating CDKN1A
    Bi, Mingjun
    Yu, Hongmei
    Huang, Bin
    Tang, Cuiyan
    [J]. GENE, 2017, 626 : 337 - 343
  • [8] Chang H, 2010, BONE MARROW TRANSPL, V45, P117, DOI 10.1038/bmt.2009.107
  • [9] Clinical significance of TP53 mutation in myeloma
    Chng, W. J.
    Price-Troska, T.
    Gonzalez-Paz, N.
    Van Wier, S.
    Jacobus, S.
    Blood, E.
    Henderson, K.
    Oken, M.
    Van Ness, B.
    Greipp, P.
    Rajkumar, S. V.
    Fonseca, R.
    [J]. LEUKEMIA, 2007, 21 (03) : 582 - 584
  • [10] MALAT1 long non-coding RNA is overexpressed in multiple myeloma and may serve as a marker to predict disease progression
    Cho, Shih-Feng
    Chang, Yuli Christine
    Chang, Chao-Sung
    Lin, Sheng-Fung
    Liu, Yi-Chang
    Hsiao, Hui-Hua
    Chang, Jan-Gowth
    Liu, Ta-Chih
    [J]. BMC CANCER, 2014, 14